e-Drug3D

891

RIFAXIMIN

INN
RIFAXIMIN

cas 80621-81-4

CLASS

METABOLISM
ANTIINFECTIVE AGENTS
GASTROINTESTINAL AGENTS
TREATMENT OF TRAVELERS’ DIARRHEA
STRUCTURAL ANALOG OF RIFAMPIN
INHIBITION OF BACTERIAL RNA SYNTHESIS

ROUTE (list)

ORAL

ATC code

A07AA11
D06AX11

PK parameters

Tmax 0.8 HOUR
PPB 67.5 PERCENT
t1/2 1.8 HOUR

Target

TARGET DNA-DEPENDANT RNA POLYMERASE BETA CHAIN

PDB
6BEE (CRYSTAL STRUCTURE OF VACV D13 IN COMPLEX WITH RIFAXIMIN)

Ligand code = RXM (link to the list of PDB complexes)

Download experimental 3D coordinates of RXM with added hydrogens

DrugCentral

Bacterial DNA-directed RNA polymerase UNIPROT P0A7Z4 rpoA

Download SDF file

2S,16Z, 18E,20S,21 S,22R, 23R,24R,25S,26 S,27S,28E)-5,6,21,23, 25-pentahydroxy-27-methoxy-2,4,11,16, 20,22,24,26-octamethyl-2,7- (epoxypentadeca-[1,11,13]trienimino) benzofuro[4,5-e]pyrido[1,2-a] -benzimida-zole-1,15(2H)- dione,25-acetate

Formula:
C43H51N3O11

Calculated chemical properties:

MW 785.87
NB_atoms 57
XLogP 6.16
PSA 180.257
NB_HD 5
NB_HA 14
fsp3 0.44
Lipinski(0=no;1=yes) 0

FDA
NDA 021361 (label) INN (RIFAXIMIN) XIFAXAN (SALIX PHARMS) APPROVAL= AP YEAR= 2004
NDA 022554 (label) INN (RIFAXIMIN) XIFAXAN (SALIX PHARMS) APPROVAL= AP YEAR= 2010 NEWAPPLICATION
NDA 214369 (pdf not found) INN (RIFAXIMIN) RIFAXIMIN (NORWICH PHARMACEUTICALS INC) APPROVAL= TA YEAR= 2024
NDA 214370 (pdf not found) INN (RIFAXIMIN) RIFAXIMIN (NORWICH) APPROVAL= TA YEAR= 2025
NDA 213713 (pdf not found) INN (RIFAXIMIN) RIFAXIMIN (SANDOZ INC) APPROVAL= TA YEAR= 2025
NDA 218650 (pdf not found) INN (RIFAXIMIN) RIFAXIMIN (ZYDUS PHARMS USA INC) APPROVAL= TA YEAR= 2025